rhuFVIIa in Post-partum Hemorrhage
Postpartum Hemorrhage
About this trial
This is an interventional treatment trial for Postpartum Hemorrhage focused on measuring Post-partum hemorrhage, Arterial embolization, Surgery, Hysterectomy, Activated recombinant human factor VII
Eligibility Criteria
Inclusion Criteria: Severe postpartum hemorrhage, i.e non responsive to sulprostone infusion Exclusion Criteria: < 18 years personal antecedent of arterial or venous thrombosis written informed consent not approved/signed by the patient or her husband
Sites / Locations
- Hôpital Antoine Béclère -APHP
- University Hospital, Lille
- University Hospital of Montpellier
- University Hospital, Nice
- Laboratoire d'hématologie, Groupe Hospitalo-Universitaire Caremeau
- Centre Hospital University of Nimes
- Maternite CHU de Cochin - APHP
- University Hospital, Geneva
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Standard care for post-partum hemorrhage
rFVIIa
The patients included in this arm of the study will recieve standard care for post-partum hemorrhage.
The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)